Breaking News Instant updates and real-time market news.

BOLD

Audentes Therapeutics

$18.43

0.32 (1.77%)

, AVXS

AveXis

$47.51

2.35 (5.20%)

10:09
10/10/16
10/10
10:09
10/10/16
10:09

AveXis data bodes well for Audentes gene therapy program, says Piper Jaffray

Piper Jaffray analyst Joshua Schimmer said additional data presented by AveXis (AVXS) from its ongoing Phase 1/2 trial in infantile-onset spinal muscular atrophy "augurs well" for Audentes Therapeutics' (BOLD) gene therapy program for X-linked myotubular myopathy, as he sees several points of similarity that provide a positive read-through though the companies are targeting different diseases. Schimmer, who does not have a rating on AveXis, reiterates his Overweight rating and $24 price target on Audentes shares.

BOLD

Audentes Therapeutics

$18.43

0.32 (1.77%)

AVXS

AveXis

$47.51

2.35 (5.20%)

  • 10

    Oct

  • 06

    Nov

BOLD Audentes Therapeutics
$18.43

0.32 (1.77%)

08/15/16
PIPR
08/15/16
INITIATION
Target $24
PIPR
Overweight
Audentes Therapeutics initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer started Audentes Therapeutics with an Overweight rating and $24 price target. The analyst views the company as well-positioned in the "rapidly evolving gene therapy landscape."
08/15/16
COWN
08/15/16
INITIATION
COWN
Outperform
Audentes Therapeutics initiated with an Outperform at Cowen
Cowen analyst Ritu Baral started Audentes Therapeutics with an Outperform rating.
08/15/16
WEDB
08/15/16
INITIATION
Target $20
WEDB
Outperform
Audentes Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated Audentes Therapeutics with an Outperform and $20 price target saying its a compelling opportunity in AAV gene therapy of rare diseases.
AVXS AveXis
$47.51

2.35 (5.20%)

09/26/16
PIPR
09/26/16
NO CHANGE
Target $46
PIPR
Overweight
Ionis nusinersen program advancing faster than expected, says Piper Jaffray
After Biogen (BIIB) and Ionis (IONS) announced that Biogen has completed the rolling submission of a New Drug Application to the U.S. FDA for the approval of nusinersen, an investigational treatment for spinal muscular atrophy, Piper Jaffray analyst Joshua Schimmer said that the nusinersen program is advancing faster than many have expected. Nusinersen may launch before AveXis (AVXS) starts its next Phase 3 trial, added Schimmer, who believes nusinersen will emerge as a multi-billion dollar product. The analyst keeps an Overweight rating and $46 price target on Ionis shares.
09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
10/06/16
GSCO
10/06/16
NO CHANGE
Target $71
GSCO
Buy
AveXis attractive acquisition target, price target to $71 at Goldman
Goldman analyst Salveen Richter said AveXis has two approaching catalysts coming up, the AVXS-101 update in SMA Type 1 at the World Muscle Society, or WMS, on October 8, and clarity on the AVXS-101 pivotal trial design in late October/early November. The analyst expects positive WMS data and raaised his probability of success to 60% from 45%. He expects compelling motor milestone data and pivotal trial visibility to make AveXis an attractive acquisition target and raised his price target to $71 from $46 on shares and reiterated his Buy rating.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).

TODAY'S FREE FLY STORIES

V

Visa

$102.90

-2.665 (-2.52%)

14:50
09/25/17
09/25
14:50
09/25/17
14:50
Options
Bullish option play opened in Visa as shares slump »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Nov

RHT

Red Hat

$105.41

-0.89 (-0.84%)

14:49
09/25/17
09/25
14:49
09/25/17
14:49
Options
Red Hat options imply 10.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

APRN

Blue Apron

$5.47

0.28 (5.40%)

14:45
09/25/17
09/25
14:45
09/25/17
14:45
Options
Blue Apron call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIP

TripAdvisor

$44.37

0.125 (0.28%)

, PCLN

Priceline

$1,862.13

-4.22 (-0.23%)

14:42
09/25/17
09/25
14:42
09/25/17
14:42
Hot Stocks
Analysts trim TripAdvisor estimates on increasing online travel concerns »

Shares of TripAdvisor…

TRIP

TripAdvisor

$44.37

0.125 (0.28%)

PCLN

Priceline

$1,862.13

-4.22 (-0.23%)

TRVG

trivago

$10.70

-0.04 (-0.37%)

EXPE

Expedia

$145.77

2.65 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DY

Dycom

$81.51

-1.185 (-1.43%)

14:36
09/25/17
09/25
14:36
09/25/17
14:36
Conference/Events
Dycom management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

DY

Dycom

$81.56

-1.13 (-1.37%)

14:35
09/25/17
09/25
14:35
09/25/17
14:35
Options
Dycom put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

14:31
09/25/17
09/25
14:31
09/25/17
14:31
Technical Analysis
Technical View: Amazon.com falls, topping process confirmed »

The shares are down 2.1%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

DIS

Disney

$99.37

0.77 (0.78%)

14:27
09/25/17
09/25
14:27
09/25/17
14:27
Recommendations
Disney analyst commentary  »

Disney approach to price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

ESV

Ensco

$5.77

0.53 (10.11%)

14:25
09/25/17
09/25
14:25
09/25/17
14:25
Options
Ensco call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 05

    Oct

NFLX

Netflix

$187.35

-1.43 (-0.76%)

14:21
09/25/17
09/25
14:21
09/25/17
14:21
Technical Analysis
Technical View: Netflix trades near lows of the day »

The shares are down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    Oct

  • 22

    Oct

$NSD

NASDAQ Market Internals

14:17
09/25/17
09/25
14:17
09/25/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
09/25/17
09/25
14:16
09/25/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GREK

Global X MSCI Greece ETF

$9.18

-0.635 (-6.47%)

14:10
09/25/17
09/25
14:10
09/25/17
14:10
Options
MSCI Greek Fund puts are active as shares falter »

MSCI Greek Fund puts are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$13.30

-0.11 (-0.82%)

, NVDA

Nvidia

$179.00

-1.76 (-0.97%)

14:08
09/25/17
09/25
14:08
09/25/17
14:08
Hot Stocks
AMD, NVIDIA fall after Intel unveils next generation of core processors »

Shares of AMD (AMD) and…

AMD

AMD

$13.30

-0.11 (-0.82%)

NVDA

Nvidia

$179.00

-1.76 (-0.97%)

INTC

Intel

$37.18

-0.02 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Oct

  • 22

    Oct

HLF

Herbalife

$67.51

-0.06 (-0.09%)

14:06
09/25/17
09/25
14:06
09/25/17
14:06
Hot Stocks
FTC grants Carl Icahn clearance for additional Herbalife purchases »

The Federal Trade…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YY

YY

$80.52

4.45 (5.85%)

14:05
09/25/17
09/25
14:05
09/25/17
14:05
Options
YY call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
09/25/17
09/25
14:05
09/25/17
14:05
General news
Treasury Option Action: heavy put spread demand at the short-end »

Treasury Option Action:…

RCII

Rent-A-Center

$10.80

-0.07 (-0.64%)

13:55
09/25/17
09/25
13:55
09/25/17
13:55
Options
Rent A Center put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:55
09/25/17
09/25
13:55
09/25/17
13:55
Conference/Events
Senate Finance Committee holds a hearing »

The Committee holds a…

GS

Goldman Sachs

$230.10

-0.93 (-0.40%)

13:54
09/25/17
09/25
13:54
09/25/17
13:54
Periodicals
Symphony to raise $100M to expand, The Information says »

Goldman Sachs-backed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 17

    Oct

  • 22

    Oct

AMDA

Amedica

$0.33

0.005 (1.56%)

13:50
09/25/17
09/25
13:50
09/25/17
13:50
Downgrade
Amedica rating change  »

Amedica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SCWX

SecureWorks

$12.57

0.15 (1.21%)

13:47
09/25/17
09/25
13:47
09/25/17
13:47
Hot Stocks
Breaking Hot Stocks news story on SecureWorks »

ETF Managers Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

$36.59

0.81 (2.26%)

13:45
09/25/17
09/25
13:45
09/25/17
13:45
Options
Devon Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

13:45
09/25/17
09/25
13:45
09/25/17
13:45
General news
Treasury Action: coupon supply commences Tuesday »

Treasury Action: coupon…

ADP

ADP

$108.16

1.37 (1.28%)

13:43
09/25/17
09/25
13:43
09/25/17
13:43
Hot Stocks
Pershing: ADP overstates shareholder return during CEO's tenure »

Pershing Square Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.